13th Annual Conference of the National HIV Nurses Association (NHIVNA)



Nicky Perry

Brighton and Sussex University
Hospitals NHS Trust

16-17 June 2011, Arena and Convention Centre, Liverpool

Ten Key Lessons from HIV Research

Nicky Perry
Research Manager HIV/GUM
Brighton and Sussex University
Hospitals NHS Trust

Brighton and Sussex **NHS**University Hospitals

HIV epidemic at 30 years The Early Years



June 5th 1981




Jade Goody was born



Adam Ant was UK number 1 with Stand and Deliver

1981: Israel bombs Baghdad nuclear reactor

Israel shocks the world by destroying the Osirak nuclear plant near the Iraqi capital for fear it would be used to make atom bombs.





Piecing things together..

- First link of HIV being blood borne virus
- Pattern of unusual symptoms in patients, the task force named the condition acquired immune deficiency syndrome (AIDS)
- Risk groups for HIV emerging
 - Heterosexuals
 - Infants of infected mothers
 - Haemophilliacs
 - Injecting Drug Users
- Fear and denial even among the medical profession to discuss **HIV/AIDS**

In 1984, Science published two separate articles in the same issue

Robert Gallo claimed that a virus from an AIDS patient was strikingly similar in shape to other human T-cell viruses (HTLVs) and called his newly isolated virus HTLV-III



- Luc Montagnier isolated a virus from a gay man patient with swollen lymph nodes different from HTLV-I. They named their isolated virus lymphadenopathy-associated virus (LAV)
- HIV was chosen as a compromise between the two claims (LAV and HTLV-III) Montagnier was awarded half a Nobel Prize










- Nursing care issues
 - Palliative care
 - Multidisciplinary team approach
 - Patient IV admin
 - Chemotherapy
 - Patient led
- Patients with complex medical conditions





1989 - ACTG 019

- Halted after 1 year
- AZT seemed to delay progression of disease




HIV epidemic at 30 years The Middle Years






Concorde Study




ACTG 076

Mother to Child Transmission




Combination therapy



Results

- 3,000 patients
- Prolongs life and delays disease progression



Viral load testing
Protease Inhibitors
Triple Therapy

World AIDS Conference
Vancouver 1996....
...the era of triple-therapy with PIs
begins



22

The Battle....



23


Early PIs – dosing


- Saquinavir¹
 - 600mg TID
- Indinavir²
 - 800mg every 8 hours
- Ritonavir³
 - 600mg (liquid) BID


24


Vella S et al. Antivir Ther 1996;1(3):129-140.
 Gulick RM et al. N Engl J Med 1997; 337(11): 734-739.
 Cameron DW for the Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351: 543-549.

Protease Inhibitors work!

















HIV epidemic at 30 years The Later Years





Adherence

Paterson 2000 – "adherence ≥ 95% optimises virologic outcome"
 ¹ Based on data from Rx-experienced populations on unboosted PI and 2 NUCs²

NNRTI

NNRTI


0-53
(n=27)


Adherence, %


Data from 110 HIV-infected patients initiating 1st cART including an unboosted PI or NNRTI (efavirenz, nevirapine) Adapted from: 1. Paterson DL et al. Ann Intern Med 2000; 1333:21–30; 2. Bangsberg D et al. Clin Infect Dis 2006; 43:939–941.


Lesson 8

Emergence of new issues













Right drug, right time New Classes













Prevention

CAPRISA 004 assessed the safety and effectiveness of 1% tenofovir gel


- BAT 24 coitally-related gel use
 - Insert 1 gel up to 12 hours Before sex,
 - insert 1 gel as soon as possible within 12 hours <u>A</u>fter sex,
 - no more than <u>T</u>wo doses in <u>24</u> hours









48







Mma Bana: Primary MTCT Endpoint Shapiro R et al. IAS, Capetown, South Africa, July 2009, Abs.			
Infections among live-born infants, by maternal arm	Arm A (TZV) N=283	Arm B (KAL/CBV) N=270	Obs Arm (NVP/CBV) N=156
In utero	3 (1.1%)*	1 (0.4%)	1 (0.6%)
Intrapartum	0	0	0
Breastfeeding	2 (0.7%)	0	0
Total at 6 months	5 (1.8%)*	1 (0.4%)	1 (0.6%)
P=0.53			

Overall Transmission 1% (95% CI, 0.5-2.0%) Through Age 6 Months







Acknowledgements

Dr Laura Waters
Dr Martin Fisher
www.avert.org